Rocket Lab Bets $8 Billion to Challenge SpaceX's Starlink Dominance
Rocket Lab is acquiring Iridium in an $8 billion deal, framing the move as a strategic shortcut to competing in satellite connectivity.
Rocket Lab, long known as a scrappy launch provider working in SpaceX's shadow, is making its most audacious move yet: an $8 billion acquisition of Iridium, the established satellite communications company. The deal signals that Rocket Lab is no longer content to simply put payloads into orbit — it wants a direct piece of the lucrative satellite connectivity market that SpaceX's Starlink has come to dominate.
Company leadership described the Iridium acquisition explicitly as a "shortcut," a candid admission that building a competing satellite network from scratch would take years and tens of billions of dollars. By absorbing Iridium's existing constellation and customer base, Rocket Lab is attempting to compress what would otherwise be a decade-long infrastructure buildout into a single transaction. That kind of strategic logic — buying time as much as buying assets — reflects how seriously the industry takes Starlink's head start.
Read more Comcast to Spin Off NBCUniversal and Sky in Major Restructuring →
Iridium is not a trivial acquisition target. The company operates one of the few truly global satellite networks, with coverage extending to the poles where many competitors cannot reach. That geographic reach, combined with an established enterprise and government customer base, gives Rocket Lab something Starlink still lacks in certain regulated and defense-adjacent markets: a proven, trusted communications infrastructure with deep institutional relationships.
The deal also reframes what Rocket Lab is as a company. It entered the market as a launch specialist with its Electron rocket and has been developing the larger Neutron vehicle. Folding in Iridium transforms it into an end-to-end space services business — one that can launch, operate, and monetize satellites. Whether that vertical integration becomes a competitive advantage or a costly distraction will be the central question investors and analysts are likely to wrestle with as the acquisition moves through regulatory review.
Continue reading at MarketWatch.com
